REGENXBIO (RGNX) Stock Forecast & Price Target

Regenxbio is currently a speculative investment, with a positive perception among financial analysts due to its promising pipeline of gene therapy treatments using its NAV Technology Platform. One key financial metric to watch is the company's market value, which is currently estimated at $1.64B. However, there are risks to achieving the projected 12-month price target, including the failure of gene therapy candidates in clinical trials and regulatory approval, as well as potential competition and market size limitations. Overall, while Regenxbio's CSF HS D2S6 surrogate endpoint may need additional evidence to support its ability to predict clinical benefit, the company's future prospects remain promising with potential launches of its higher-priority programs in 2021 and a diversified pipeline of partnerships.

Regenxbio is facing a potential delay in the approval of its lead gene therapy candidate, RGX-121, for the treatment of mucopolysaccharidosis type II (MPS II), following the receipt of a complete response letter (CRL) from the FDA due to concerns surrounding the study eligibility criteria and the use of a surrogate endpoint. This, combined with the clinical hold on other gene therapy programs for the company, highlights the potential risks involved with investing in the novel and complex area of gene therapy. Additionally, the company's heavy reliance on partnerships and a heavy focus on rare diseases may further constrain its financial potential.